← All trials
NCT06738485
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2025
- Primary completion
- Feb 26, 2026
- Completion date
- Feb 26, 2026
- First posted
- Dec 17, 2024
- Last posted
- Dec 17, 2024
- Enrollment
- 60
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- CSL BehringLead sponsor
- CSL BehringOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.